Provell Pharmaceuticals has filed a notice of an exempt offering of securities to raise $2,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Provell Pharmaceuticals is raising $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jim Small played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Provell Pharmaceuticals
We are a private healthcare company specializing in the marketing and distribution of world class leading pharmaceutical products in the United States. Our goal is to provide unique and innovative delivery of pharmaceutical products enhancing drug quality/stability, better patient adherence and outcomes, all at a lower cost.
To learn more about Provell Pharmaceuticals, visit http://www.provellpharma.com/
Contact:
Jim Small, Chief Executive Officer
610-942-9455
https://www.linkedin.com/in/jim-small-52681a10/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.